Investors often target blue-chip ASX 200 shares for lower volatility and consistent earnings.
It’s often assumed that because these companies are well-established, there is limited upside.
However, here are some blue-chip stocks that have recently received price targets from brokers indicating upside of 20% or more.Â
Qantas Airways Ltd (ASX: QAN)
With oil prices skyrocketing and geopolitical tension impacting global travel, Qantas shares have faced some volatility recently.
The company noted that it is facing uncertainty due to Middle East tensions and rising jet fuel refining margins.
However, it has hedged crude oil exposure and remains confident in fuel supply through April and May.
Strong international demand – especially to Europe – has led the airline to redeploy aircraft and cut domestic capacity, with higher airfares expected to lift unit revenue by about 5% in the second half of FY26.
These headwinds have pushed its stock price down by 12% year to date.
In good news for prospective buyers, the Qantas share price could now be a significant value.
Macquarie recently placed a $11 price target on the airline’s shares, which would be a 20% rise from the share price at the time of writing.Â
As a bonus, experts are tipping a healthy dividend yield for the ASX 200 company throughout the next few years.
Telix Pharmaceuticals Ltd (ASX: TLX)
Like many ASX 200 healthcare shares, the Telix stock price has fallen heavily in the last 12 months.
However, the commercial-stage biopharmaceutical company has rebounded significantly over the past month.
Brokers believe this could be the start of a longer rally.
Recently, Bell Potter placed a buy rating and $19 price target on Telix shares after the company announced the refinancing of its convertible note facility.
The share price at the time of writing is hovering around $14.59, which indicates an upside potential of 30%.Â
Life360 Inc (ASX: 360)
Despite now climbing 26% over the last 6 days at the time of writing, the Life360 share price remains significantly below its yearly highs.Â
The company’s core product is a private family and friends social networking app that allows users to communicate and share their locations.
At the time of writing, this ASX 200 stock is exchanging hands for $22.72 per share.
However, this is significantly below the $36.02 average price targets of 10 analysts via TradingView.
Should this ASX 200 stock reach that level in the next 12 months, it would be a 58% rise from current levels.
The post 3 ASX 200 shares tipped to rise 20% or more appeared first on The Motley Fool Australia.
Should you invest $1,000 in Qantas Airways Limited right now?
Before you buy Qantas Airways Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Qantas Airways Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Experts name 3 ASX 200 tech shares to buy now
- 2 ASX shares highly recommended to buy: Experts
- These are the 10 most shorted ASX shares
- ASX 200 tech shares rocket 13% as long-awaited sector rebound accelerates
- Top brokers name 3 ASX shares to buy next week
Motley Fool contributor Aaron Bell has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360, Macquarie Group, and Telix Pharmaceuticals. The Motley Fool Australia has positions in and has recommended Life360 and Macquarie Group. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.